Sort by

Send to

Choose Destination

Links from PubMed

Items: 1 to 20 of 94


Chemoresistance in ovarian cancer linked to expression of microRNAs.

Frederick PJ, Green HN, Huang JS, Egger ME, Frieboes HB, Grizzle WE, McNally LR.

Biotech Histochem. 2013 Oct;88(7):403-9. doi: 10.3109/10520295.2013.788736.


Role of microRNAs in drug-resistant ovarian cancer cells.

Sorrentino A, Liu CG, Addario A, Peschle C, Scambia G, Ferlini C.

Gynecol Oncol. 2008 Dec;111(3):478-86. doi: 10.1016/j.ygyno.2008.08.017.


Low MAD2 expression levels associate with reduced progression-free survival in patients with high-grade serous epithelial ovarian cancer.

Furlong F, Fitzpatrick P, O'Toole S, Phelan S, McGrogan B, Maguire A, O'Grady A, Gallagher M, Prencipe M, McGoldrick A, McGettigan P, Brennan D, Sheils O, Martin C, W Kay E, O'Leary J, McCann A.

J Pathol. 2012 Apr;226(5):746-55. doi: 10.1002/path.3035. Erratum in: J Pathol. 2014 Feb;232(3):e1.


Identification of ovarian cancer metastatic miRNAs.

Vang S, Wu HT, Fischer A, Miller DH, MacLaughlan S, Douglass E, Comisar L, Steinhoff M, Collins C, Smith PJ, Brard L, Brodsky AS.

PLoS One. 2013;8(3):e58226. doi: 10.1371/journal.pone.0058226. Erratum in: PLoS One. 2014;9(1). doi:10.1371/annotation/aeb6ccee-921a-4250-a18c-4ea633b984dd. Comisar, Lauren [added].


Differential miRNA expression profiles in hepatocellular carcinoma cells and drug-resistant sublines.

Zhuo L, Liu J, Wang B, Gao M, Huang A.

Oncol Rep. 2013 Feb;29(2):555-62. doi: 10.3892/or.2012.2155.


MyD88 predicts chemoresistance to paclitaxel in epithelial ovarian cancer.

Silasi DA, Alvero AB, Illuzzi J, Kelly M, Chen R, Fu HH, Schwartz P, Rutherford T, Azodi M, Mor G.

Yale J Biol Med. 2006 Dec;79(3-4):153-63.


Reversal of paclitaxel resistance in epithelial ovarian carcinoma cells by a MUC1 aptamer-let-7i chimera.

Liu N, Zhou C, Zhao J, Chen Y.

Cancer Invest. 2012 Oct;30(8):577-82.


Upregulation of Periostin and Reactive Stroma Is Associated with Primary Chemoresistance and Predicts Clinical Outcomes in Epithelial Ovarian Cancer.

Ryner L, Guan Y, Firestein R, Xiao Y, Choi Y, Rabe C, Lu S, Fuentes E, Huw LY, Lackner MR, Fu L, Amler LC, Bais C, Wang Y.

Clin Cancer Res. 2015 Jul 1;21(13):2941-51. doi: 10.1158/1078-0432.CCR-14-3111.


Expression of RET finger protein predicts chemoresistance in epithelial ovarian cancer.

Horio M, Kato T, Mii S, Enomoto A, Asai M, Asai N, Murakumo Y, Shibata K, Kikkawa F, Takahashi M.

Cancer Med. 2012 Oct;1(2):218-29. doi: 10.1002/cam4.32.


miR-141 regulates KEAP1 and modulates cisplatin sensitivity in ovarian cancer cells.

van Jaarsveld MT, Helleman J, Boersma AW, van Kuijk PF, van Ijcken WF, Despierre E, Vergote I, Mathijssen RH, Berns EM, Verweij J, Pothof J, Wiemer EA.

Oncogene. 2013 Sep 5;32(36):4284-93. doi: 10.1038/onc.2012.433.


Smoothened antagonists reverse taxane resistance in ovarian cancer.

Steg AD, Katre AA, Bevis KS, Ziebarth A, Dobbin ZC, Shah MM, Alvarez RD, Landen CN.

Mol Cancer Ther. 2012 Jul;11(7):1587-97. doi: 10.1158/1535-7163.MCT-11-1058.


Niclosamide Analogs for Treatment of Ovarian Cancer.

Walters Haygood CL, Arend RC, Gangrade A, Chettiar S, Regan N, Hassmann CJ 2nd, Li PK, Hidalgo B, Straughn JM Jr, Buchsbaum DJ.

Int J Gynecol Cancer. 2015 Oct;25(8):1377-85. doi: 10.1097/IGC.0000000000000506.


A microRNA signature defines chemoresistance in ovarian cancer through modulation of angiogenesis.

Vecchione A, Belletti B, Lovat F, Volinia S, Chiappetta G, Giglio S, Sonego M, Cirombella R, Onesti EC, Pellegrini P, Califano D, Pignata S, Losito S, Canzonieri V, Sorio R, Alder H, Wernicke D, Stoppacciaro A, Baldassarre G, Croce CM.

Proc Natl Acad Sci U S A. 2013 Jun 11;110(24):9845-50. doi: 10.1073/pnas.1305472110.


MiR-200c and HuR in ovarian cancer.

Prislei S, Martinelli E, Mariani M, Raspaglio G, Sieber S, Ferrandina G, Shahabi S, Scambia G, Ferlini C.

BMC Cancer. 2013 Feb 8;13:72. doi: 10.1186/1471-2407-13-72.


MicroRNA profiling of a CD133(+) spheroid-forming subpopulation of the OVCAR3 human ovarian cancer cell line.

Nam EJ, Lee M, Yim GW, Kim JH, Kim S, Kim SW, Kim YT.

BMC Med Genomics. 2012 May 29;5:18. doi: 10.1186/1755-8794-5-18.


iASPP and chemoresistance in ovarian cancers: effects on paclitaxel-mediated mitotic catastrophe.

Jiang L, Siu MK, Wong OG, Tam KF, Lu X, Lam EW, Ngan HY, Le XF, Wong ES, Monteiro LJ, Chan HY, Cheung AN.

Clin Cancer Res. 2011 Nov 1;17(21):6924-33. doi: 10.1158/1078-0432.CCR-11-0588.


Combined activity of oridonin and wogonin in advanced-stage ovarian cancer cells: sensitivity of ovarian cancer cells to phyto-active chemicals.

Chen S, Cooper M, Jones M, Madhuri TK, Wade J, Bachelor A, Butler-Manuel S.

Cell Biol Toxicol. 2011 Apr;27(2):133-47. doi: 10.1007/s10565-010-9176-0.


Regulation of microtubule-associated protein tau (MAPT) by miR-34c-5p determines the chemosensitivity of gastric cancer to paclitaxel.

Wu H, Huang M, Lu M, Zhu W, Shu Y, Cao P, Liu P.

Cancer Chemother Pharmacol. 2013 May;71(5):1159-71. doi: 10.1007/s00280-013-2108-y.


MiR-222 and miR-29a contribute to the drug-resistance of breast cancer cells.

Zhong S, Li W, Chen Z, Xu J, Zhao J.

Gene. 2013 Nov 15;531(1):8-14. doi: 10.1016/j.gene.2013.08.062.

Items per page

Supplemental Content

Support Center